← Leaderboards
Murugabaskar Balan
Boston Children'S Hospital
$354,000
Attributed
$354,000
Total exposure
2
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $88.5K · FY2018–21$100K$75K$50K$25K$0
'18
'19
'20
'21
Funding mix
By agency
NIH$354,000 · 2
By mechanism
R03$354,000 · 2
Top collaborators
No co-investigators on record.
Most similar at Boston Children'S Hospital
Same institution · by research overlap
- Hidde L Ploegh$43,368,874
- Alena Yermalovich$509,184
- Morris F. White$23,937,236
- Peter V Kharchenko$5,172,146
Others in their field
Other Emerging Leaders on “Inhibitor/Antagonist”
- Susan Abushakra · Alzheon, Inc.$27,500,000
- Alan D. Palkowitz · Indiana University Indianapolis$10,342,358
- Michael-Christopher Keogh · Epicypher, Inc.$6,845,336
- Terry Roemer · Prokaryotics, Inc.$6,530,728
- Jurgen Bernd Bulitta · State University Of New York At Buffalo$6,175,581
- Aaron Esser-Kahn · University Of Chicago$5,799,408
Research focus
Inhibitor/AntagonistLeadFda ApprovedImmunotherapeutic AgentIn VivoKnock-DownAcquired Drug ResistanceExperimental StudyGene MutationHypoxiaIn VitroAdultCellsKidney NeoplasmsChemotherapyChromosomesClear CellAntitumor EffectDoseDrug ResistanceApoptosisGrowthCancer CellMediating
Grant awards (4)
Novel role of CD73 in c-Met-mediated immune escape in renal cell carcinoma$88,500
R03 · FY2021 · CA · contact PI
Novel role of CD73 in c-Met-mediated immune escape in renal cell carcinoma$88,500
R03 · FY2020 · CA · contact PI
c-Met-induced Renalase: a novel therapeutic target for renal cancer$88,500
R03 · FY2019 · CA · contact PI
c-Met-induced Renalase: a novel therapeutic target for renal cancer$88,500
R03 · FY2018 · CA · contact PI